WHO ICTRP trial
A study to provide access to idelalisib in combination with rituximab for the…
EUCTR2013-005343-82-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2013-005343-82-DE |
|---|---|
| Public title | A study to provide access to idelalisib in combination with rituximab for the treatment of previously treated chronic lymphocytic leukemia |
| Scientific title | An Expanded Access Protocol for Idelalisib in Combination with Rituximab for Relapsed, Previously Treated Subjects with Chronic Lymphocytic Leukemia |
| Primary sponsor | Gilead Sciences, Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | United States;Ireland;Germany;United Kingdom;Italy |
| Conditions | Chronic lymphocytic leukemia MedDRA version: 16.1 Level: LLT Classification code 10068919 Term: B-cell chronic lymphocytic leukemia System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Product Name: Idelalisib Product Code: GS-1101 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: IDELALISIB CAS Number: 870281-82-6 Current Sponsor code: GS-1101 Concentration unit: mg milligram(s) Concentration type: equal… |
| Registration date | Mar 25, 2014 |
| Target size | 150 |
| Secondary IDs | GS-US-312-1325 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: